Instil Bio Reports Exit/Disposal Activities on Jan 14

TL;DR

**Instil Bio is restructuring, expect one-time costs and strategic shifts.**

AI Summary

Instil Bio, Inc. filed an 8-K on January 16, 2024, reporting an event on January 14, 2024, related to 'Cost Associated with Exit or Disposal Activities' and 'Other Events'. This indicates the company is undergoing significant restructuring or winding down certain operations. For investors, this matters because such activities often involve one-time costs, potential asset sales, or a shift in strategic direction, which can impact future profitability and the company's long-term viability.

Why It Matters

This filing signals Instil Bio is likely reducing operations or divesting assets, which could lead to one-time charges and impact its financial health and strategic focus.

Risk Assessment

Risk Level: medium — Exit or disposal activities can be costly and signal operational challenges, but the specific financial impact is not yet disclosed, making the risk moderate.

Analyst Insight

Investors should monitor Instil Bio's upcoming financial reports for details on the costs and strategic implications of these exit or disposal activities, as they could significantly impact future valuations.

Key Players & Entities

• Instil Bio, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where Instil Bio's Common Stock is registered

Forward-Looking Statements

• Instil Bio will report significant one-time charges related to exit or disposal activities in its next earnings report. (Instil Bio, Inc.) — medium confidence, target: Q1 2024 Earnings Report

FAQ

Key Financial Figures

• $0.000001 — ange on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market L
• $6.1 m — aggregate restructuring costs of up to $6.1 million, including employee termination c

Filing Documents

• til-20240114.htm (8-K) — 37KB
• pr8-kexit.htm (EX-99.1) — 10KB
• image_0a.jpg (GRAPHIC) — 3KB
• 0001789769-24-000018.txt ( ) — 182KB
• til-20240114.xsd (EX-101.SCH) — 2KB
• til-20240114_lab.xml (EX-101.LAB) — 24KB
• til-20240114_pre.xml (EX-101.PRE) — 13KB
• til-20240114_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On January 14, 2024, the Board of Directors of Instil Bio, Inc. (the "Company") approved a restructuring plan (the "Plan") to effect the closure of its Manchester, UK manufacturing and clinical trial operations, thereby reducing its UK workforce by approximately 61%. This workforce reduction is expected to be substantially completed by the first half of 2024. As a result of the foregoing, the Company no longer expects to report clinical data from the ITIL-306-202 clinical trial in 2024 . In connection with the Plan, the Company estimates that it will incur aggregate restructuring costs of up to $6.1 million, including employee termination costs, including severance and other benefits, and contract termination costs. The charges that the Company expects to incur in connection with the Plan are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Pla n.

01 Other Events

Item 8.01 Other Events. On January 16, 2024, the Company issued a press release entitled "Instil Bio Announces Strategic Update." A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated January 1 6 , 202 4 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Note Regarding Forward-Looking Statements This Current Report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the scope and the timing of the restructuring and the expected costs related to the restructuring and expectations regarding, and plans concerning, the Company's facilities, which are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including the sufficiency of the Company's cash resources; the Company's ability to achieve the expected benefits of its corporate restructuring; and other risks and uncertainties affecting the Company and its development programs, including those discussed in the section titled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and in subsequent filings with the SEC. Forward-looking statements in this Current Report are made as of the date of this Current Report and the Company undertakes no duty to update any such statements unless required by law.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Instil Bio, Inc. Dated: January 16, 2024 By: /s/ Sandeep Laumas, M.D. Sandeep Laumas, M.D. Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR